Panel Discussion

Segment 8: Pathways as a Means to Deliver High-Value Care
April 27, 2016 – 
Expanding the definition of "value" beyond cost, Robert Dubois, MD, PhD, emphasized that clinical pathways need more dynamic quality metrics that provide more than just a snapshot of a patient's performance.
Segment 7: How Flexible Are Oncology Care Pathways?
April 27, 2016 – 
Panelists discussed whether there is any flexibility woven into the process of developing a clinical pathway, especially if a patient does not respond to a particular therapy or if a clinician wants to include a new therapy that may be better fit.
Segment 6: Standardizing Clinical Pathways Across Health Plans
April 27, 2016 – 
While providers would be relieved of their administrative burden, standardizing care pathways across health plans may not be an easy task, Blase Polite, MD, MPP, explains.
Segment 5: Clinical Pathways - A Shared Decision-Making Tool?
April 27, 2016 – 
Have clinical pathways in oncology developed enough for providers and patients to use them as a shared decision-making tool? Panelists provide insight.
Segment 4: How Rigorous Should Pathway Development Be?
April 27, 2016 – 
Experts discuss the need for guidelines and adequate rigor when developing a care pathway in oncology.
Segment 3: Considerations for Developing a Clinical Pathway
April 27, 2016 – 
What do pathway developers consider as they formulate cancer clinical pathways? Panelists explain.
Segment 2: What Are Oncology Care Pathways?
April 27, 2016 – 
Panel members provide their own perspective on what clinical pathways encompass.
Segment 1: Introduction of Panel Members
April 26, 2016 – 
The American Journal of Managed Care convened an expert panel to discuss the development and utility of clinical pathways in oncology care.
Segment 13: Making HCV Care Sustainable for All Patients
February 12, 2015 – 
Looking at the situation in hepatitis C and its potential impact on other conditions from a provider standpoint, Ed Cohen, PharmD, FAPhA, offers up many questions to which there may not be answers just yet.
Segment 12: A New Precedent for Healthcare
February 12, 2015 – 
The situation with hepatitis C drug costs is setting an interesting precedent for the rest of healthcare and one that needs to be watched closely, according to Keith Hoffman, PhD.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!